Watch Presentation:
Driving Product Value Without DEI? The Future of Health Outcomes Research 

Driving Product Value Without DEI? The Future of Health Outcomes Research 

As the Trump Administration takes action on DEI, the short- and long-term impacts on patients, payers, pharma, and medical device industries are in flux. While the policy discussions continue, a multi-faceted question remains: how can life science companies continue to address patients’ needs, demonstrate the value of their products in vulnerable populations, and ensure sufficient data to gain FDA approval and coverage by payers? Additionally, how will changes to the availability of DEI data affect payers that rely on this information in their clinical review processes.